Skip to main content
Clinical Trials/NCT03266302
NCT03266302
Completed
Not Applicable

Revealing Mechanisms and Investigating Efficacy of Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients With Infective Endocarditis - a Multicentric Randomized Controlled Group Sequential Trial

Jena University Hospital14 sites in 1 country288 target enrollmentJanuary 17, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Infective Endocarditis
Sponsor
Jena University Hospital
Enrollment
288
Locations
14
Primary Endpoint
SOFA Score
Status
Completed
Last Updated
last year

Overview

Brief Summary

Infective endocarditis (IE) is associated with high hospital mortality for various reasons; one of them is circulatory failure in patients who undergo cardiac surgery for IE. One discussed reason underlying circulatory failure during surgery is the release of vasodilatatory mediators and cytokines. This study examines the efficacy and safety of a hemoadsorption filter which is approved for the reduction of the concentration of cytokines in the bloodstream.

Detailed Description

The investigators assume a common standard deviation of 3.8 points and that a 1.4-point lower SOFA score in the Intervention Group is of clinical relevance.

Registry
clinicaltrials.gov
Start Date
January 17, 2018
End Date
December 31, 2020
Last Updated
last year
Study Type
Interventional
Study Design
Sequential
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • patients with infective endocarditis (according to DUKE criteria) undergoing cardiac surgery
  • informed consent
  • age ≥18 years

Exclusion Criteria

  • EuroScoreII ≤ 3
  • current participation in another interventional Trial
  • pregnancy
  • current immunosuppressive or immunomodulatory therapy (with dosing of glucocorticoids over Cushing threshold)
  • previous participation in the REMOVE study

Outcomes

Primary Outcomes

SOFA Score

Time Frame: 24 hours before until day 9 post-surgery

The investigators will test if mean SOFA scores are different for the experimental and control group.

Secondary Outcomes

  • Days on ventilator, vasopressor and renal replacement therapy(until day 30 post-surgery)
  • Overall mortality rate(until day 30 post surgery)
  • SOFA subscores(24 hours before surgery until day 9 post-surgery)
  • length of ICU and in-hospital stay(until day 30 post-surgery)
  • Changes in cytokine and cfDNA levels(24 hours before, during cardiac surgery and 24 hours after surgery)
  • incidence of stroke(until day 30 post-surgery)

Study Sites (14)

Loading locations...

Similar Trials